Department of Pediatrics, Emory University, Atlanta, Ga; Children's Healthcare of Atlanta, Atlanta, Ga.
Department of Pediatrics, Washington University, St. Louis, Mo.
J Allergy Clin Immunol Pract. 2019 Mar;7(3):915-924.e7. doi: 10.1016/j.jaip.2018.09.016. Epub 2018 Sep 26.
Recurrent preschool wheezing is a heterogeneous disorder with significant morbidity, yet little is known about phenotypic determinants and their impact on clinical outcomes.
Latent class analysis (LCA) was used to identify latent classes of recurrent preschool wheeze and their association with future exacerbations and inhaled corticosteroid (ICS) treatment response.
Data from 5 clinical trials of 1708 children aged 12 to 71 months with recurrent wheezing were merged. LCA was performed on 10 demographic, exposure, and sensitization variables to determine the optimal number of latent classes. The primary outcome was the annualized rate of wheezing exacerbations requiring systemic corticosteroids during the study intervention period; the secondary outcome was the time to first exacerbation. Exploratory analyses examined the effect of daily ICS treatment on exacerbation outcomes.
Four latent classes of recurrent wheezing were identified; these were not distinguished by current symptoms or historical exacerbations but differed with regard to allergen sensitization and/or exposures. Annualized exacerbation rates (mean ± SEM/year) were 0.65 ± 0.06 for class 1 ("minimal sensitization"), 0.93 ± 0.10 for class 2 ("sensitization with indoor pet exposure"), 0.60 ± 0.07 for class 3 ("sensitization with tobacco smoke exposure"), and 0.81 ± 0.10 for class 4 ("multiple sensitization and eczema") (P < .001). In a research setting of high adherence, daily ICS treatment improved exacerbation rates in classes 2 and 4 but not the other groups.
Sensitization and exposure assessments are useful in the prediction of future exacerbation and may identify children most likely to respond favorably to daily ICS treatment.
反复性学龄前喘息是一种具有显著发病率的异质性疾病,但人们对其表型决定因素及其对临床结局的影响知之甚少。
采用潜在类别分析(LCA)来确定反复性学龄前喘息的潜在类别及其与未来加重和吸入皮质类固醇(ICS)治疗反应的相关性。
合并了 5 项针对 1708 名 12 至 71 月龄反复喘息儿童的临床试验数据。采用 LCA 对 10 个人口统计学、暴露和致敏变量进行分析,以确定潜在类别数的最优值。主要结局是研究干预期间需要全身皮质类固醇治疗的喘息加重的年化率;次要结局是首次加重的时间。探索性分析考察了每日 ICS 治疗对加重结局的影响。
确定了 4 种反复性喘息的潜在类别;这些潜在类别不能通过当前症状或既往加重来区分,但在过敏原致敏和/或暴露方面存在差异。年化加重率(均值 ± SEM/年)分别为:1 类(“最小致敏”)为 0.65 ± 0.06,2 类(“室内宠物暴露致敏”)为 0.93 ± 0.10,3 类(“烟草烟雾暴露致敏”)为 0.60 ± 0.07,4 类(“多重致敏和特应性皮炎”)为 0.81 ± 0.10(P <.001)。在高依从性的研究环境中,每日 ICS 治疗改善了 2 类和 4 类患者的加重率,但对其他组无影响。
致敏和暴露评估有助于预测未来的加重,并且可能确定最有可能对每日 ICS 治疗有良好反应的儿童。